Plasma MiR-187* is a Potential Biomarker for Oral Carcinoma

Overview

Journal Clin Oral Investig

Specialty Dentistry

Date 2016 Jun 22

PMID 27324473

Citations 18

Authors

Chung-Ji Liu

Jiun-Sheng Lin

Hui-Wen Cheng

Ya-Hui Hsu

Chieh-Yuan Cheng

Shu-Chun Lin

Affiliations

Soon will be listed here.

Abstract

Objectives: Oral squamous cell carcinoma (OSCC) is prevalent worldwide, and survival in OSCC has not improved significantly in the past decades. MicroRNAs (miRNAs) have an important regulatory role in oral carcinogenesis. This study investigated the functional and clinical implications of miR-187* in OSCC pathogenesis.

Materials And Methods: Expression of miR-187* in OSCC tissues and patient plasma was assayed using quantitative RT-PCR. The diagnostic power was specified using receiver operator curve analysis. The phenotypic influence of miR-187* in OSCC cells was delineated using exogenous expression.

Results: miR-187* was upregulated in OSCC tissue relative to control mucosa. Overexpression of miR-187* enhanced the oncogenic phenotype of OSCC cells, including cell migration and anchorage-independent colony formation. Plasma miR-187* levels could be used to distinguish patients from controls with a separating power of 0.73. Patients showing a reduction in plasma miR-187* after tumor resection had a better prognosis.

Conclusion: miR-187* plays oncogenic roles in oral carcinogenesis. Plasma miR-187* could be validated as a marker of OSCC for diagnostic uses.

Clinical Relevance: This research implied that plasma miR-187* was a diagnostic marker for patients with OSCC, and plasma miR-187* level could be a prognostic factor for OSCC patients who received ablation surgery.

Citing Articles

Developments and future prospects of personalized medicine in head and neck squamous cell carcinoma diagnoses and treatments.

Jayawickrama S, Ranaweera P, Pradeep R, Jayasinghe Y, Senevirathna K, Hilmi A Cancer Rep (Hoboken). 2024; 7(3):e2045.

PMID: 38522008 PMC: 10961052. DOI: 10.1002/cnr2.2045.

Relevance of micro-RNAs and their targets as a diagnostic and prognostic marker in oral squamous cell carcinoma.

Thomas P, Preethi K, Selvakumar S, Ramani P, Sekar D J Oral Maxillofac Pathol. 2023; 27(2):364-373.

PMID: 37854932 PMC: 10581285. DOI: 10.4103/jomfp.jomfp_349_22.

Accumulated X-ray irradiation induces miR-187-5p upregulation mediating fibrotic buccal mucosal fibroblasts activities via DKK2.

Zheng G, Xu S J Dent Sci. 2023; 18(3):1164-1169.

PMID: 37404627 PMC: 10316441. DOI: 10.1016/j.jds.2022.10.022.

Circulating miRNA as a Biomarker in Oral Cancer Liquid Biopsy.

Roi A, Boia S, Rusu L, Roi C, Boia E, Rivis M Biomedicines. 2023; 11(3).

PMID: 36979943 PMC: 10046112. DOI: 10.3390/biomedicines11030965.

Identification of novel miRNAs potentially involved in the pathogenesis of adult T-cell leukemia/lymphoma using WGCNA followed by RT-qPCR test of hub genes.

Shayeghpour A, Forghani-Ramandi M, Solouki S, Hosseini A, Hosseini P, Khodayar S Infect Agent Cancer. 2023; 18(1):12.

PMID: 36841815 PMC: 9968414. DOI: 10.1186/s13027-023-00492-0.

References

Wu J, Lu C, Diao N, Zhang S, Wang S, Wang F . Analysis of microRNA expression profiling identifies miR-155 and miR-155* as potential diagnostic markers for active tuberculosis: a preliminary study. Hum Immunol. 2011; 73(1):31-7. DOI: 10.1016/j.humimm.2011.10.003. View

Wijnhoven B, Hussey D, Watson D, Tsykin A, Smith C, Z Michael M . MicroRNA profiling of Barrett's oesophagus and oesophageal adenocarcinoma. Br J Surg. 2010; 97(6):853-61. DOI: 10.1002/bjs.7000. View

Zhou H, Huang X, Cui H, Luo X, Tang Y, Chen S . miR-155 and its star-form partner miR-155* cooperatively regulate type I interferon production by human plasmacytoid dendritic cells. Blood. 2010; 116(26):5885-94. DOI: 10.1182/blood-2010-04-280156. View

Tu H, Chang K, Cheng H, Liu C . Upregulation of miR-372 and -373 associates with lymph node metastasis and poor prognosis of oral carcinomas. Laryngoscope. 2015; 125(11):E365-70. DOI: 10.1002/lary.25464. View

Liu C, Tsai M, Hung P, Kao S, Liu T, Wu K . miR-31 ablates expression of the HIF regulatory factor FIH to activate the HIF pathway in head and neck carcinoma. Cancer Res. 2010; 70(4):1635-44. DOI: 10.1158/0008-5472.CAN-09-2291. View

Bloomston M, Frankel W, Petrocca F, Volinia S, Alder H, Hagan J . MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA. 2007; 297(17):1901-8. DOI: 10.1001/jama.297.17.1901. View

Hung P, Chang K, Kao S, Chu T, Liu C, Lin S . Association between the rs2910164 polymorphism in pre-mir-146a and oral carcinoma progression. Oral Oncol. 2011; 48(5):404-8. DOI: 10.1016/j.oraloncology.2011.11.019. View

Li J, Huang H, Sun L, Yang M, Pan C, Chen W . MiR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor. Clin Cancer Res. 2009; 15(12):3998-4008. DOI: 10.1158/1078-0432.CCR-08-3053. View

Chao A, Lin C, Lee Y, Tsai C, Wei P, Hsueh S . Regulation of ovarian cancer progression by microRNA-187 through targeting Disabled homolog-2. Oncogene. 2011; 31(6):764-75. DOI: 10.1038/onc.2011.269. View

10.

Chatterjee S, Fasler M, Bussing I, Grosshans H . Target-mediated protection of endogenous microRNAs in C. elegans. Dev Cell. 2011; 20(3):388-96. DOI: 10.1016/j.devcel.2011.02.008. View

11.

Mulrane L, Madden S, Brennan D, Gremel G, McGee S, McNally S . miR-187 is an independent prognostic factor in breast cancer and confers increased invasive potential in vitro. Clin Cancer Res. 2012; 18(24):6702-13. DOI: 10.1158/1078-0432.CCR-12-1420. View

12.

Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K . Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008; 18(10):997-1006. DOI: 10.1038/cr.2008.282. View

13.

Guo L, Lu Z . The fate of miRNA* strand through evolutionary analysis: implication for degradation as merely carrier strand or potential regulatory molecule?. PLoS One. 2010; 5(6):e11387. PMC: 2894941. DOI: 10.1371/journal.pone.0011387. View

14.

Jiang L, Lin C, Song L, Wu J, Chen B, Ying Z . MicroRNA-30e* promotes human glioma cell invasiveness in an orthotopic xenotransplantation model by disrupting the NF-κB/IκBα negative feedback loop. J Clin Invest. 2011; 122(1):33-47. PMC: 3248293. DOI: 10.1172/JCI58849. View

15.

Ambros V . The functions of animal microRNAs. Nature. 2004; 431(7006):350-5. DOI: 10.1038/nature02871. View

16.

Lu Y, Chen Y, Wang H, Tsai C, Chen W, Huang Y . Oncogenic function and early detection potential of miRNA-10b in oral cancer as identified by microRNA profiling. Cancer Prev Res (Phila). 2012; 5(4):665-74. DOI: 10.1158/1940-6207.CAPR-11-0358. View

17.

Shieh T, Lin S, Liu C, Chang S, Ku T, Chang K . Association of expression aberrances and genetic polymorphisms of lysyl oxidase with areca-associated oral tumorigenesis. Clin Cancer Res. 2007; 13(15 Pt 1):4378-85. DOI: 10.1158/1078-0432.CCR-06-2685. View

18.

Mah S, Buske C, Humphries R, Kuchenbauer F . miRNA*: a passenger stranded in RNA-induced silencing complex?. Crit Rev Eukaryot Gene Expr. 2010; 20(2):141-8. DOI: 10.1615/critreveukargeneexpr.v20.i2.40. View

19.

Wong T, Liu X, Wong B, Ng R, Yuen A, Wei W . Mature miR-184 as Potential Oncogenic microRNA of Squamous Cell Carcinoma of Tongue. Clin Cancer Res. 2008; 14(9):2588-92. DOI: 10.1158/1078-0432.CCR-07-0666. View

20.

Hung P, Liu C, Chou C, Kao S, Yang C, Chang K . miR-146a enhances the oncogenicity of oral carcinoma by concomitant targeting of the IRAK1, TRAF6 and NUMB genes. PLoS One. 2013; 8(11):e79926. PMC: 3841223. DOI: 10.1371/journal.pone.0079926. View